To investigate the role of SYY in modulating the proportion of CSCs in vivo, we examined tumor tissues by immunohistochemistry and observed a decreased proportion of ABCG2-, CD44-, ALDH1-, EpCAM-, and CD90-positive CSCs after cotreatment with SYY and oxaliplatin compared with oxaliplatin treatment alone. The gene discussed is EPCAM; the disease is neoplasm.